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Abstract
 .Atrial natriuretic peptide ANP regulates diverse physiological responses by binding to its specific guanylyl cyclase-A
 .receptor Npra which synthesizes the intracellular second messenger cGMP. To understand the molecular mechanisms of
 .cellular signaling of ANP, we have studied its effect on the enzymatic activity of overexpressed protein kinase C PKC in
 .murine Leydig tumor MA-10 cells which were transfected with PKC-a cDNA. Treatments with 12-0-tetradecanoylphor-
 .  .  .bol-13-acetate TPA , angiotensin II ANG II and endothelin-1 ET-1 stimulated the PKC activity by 4–5-fold in PKC-a
cDNA transfected MA-10 cells. The pretreatment of PKC-a transfected cells with ANP significantly inhibited the TPA-,
ANG II- and ET-1-stimulated PKC activity. The agonist-stimulated PKC activity was also inhibited in the presence of
8-bromo-cGMP, however, cAMP had no effect on stimulatory PKC activity. The exposure of cells to Npra- antagonist
A71915, which blocks the production of cGMP, significantly reduced the inhibitory effect of ANP on agonist-stimulated
PKC activity and accumulation of intracellular cGMP in MA-10 cells. Similarly, inhibition of cGMP-dependent protein
kinase by KT5823, restored the stimulatory levels of PKC activity in the presence of ANP. These results provide direct
evidence that ANP antagonizes the agonist-stimulated PKC activity in MA-10 cells, involving the specific receptor Npra, its
second messenger cGMP and cGMP-dependent protein kinase. Together, these findings implicate that ANP may act as a
negative mediator of ‘cross-talk’ between PKC-a and Npra signaling pathway in MA-10 cells.
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1. Introduction
 .Atrial natriuretic peptide ANP elicits multiple
physiological responses primarily directed at the re-
w xduction of blood pressure and fluid volume 1 . In
addition to its natriuretic, diuretic and vasorelaxant
activities, ANP inhibits the release of aldosterone,
renin and vasopressin while stimulating the release of
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wandrogen, progesterone and growth hormone for re-
w xxview, see 2–4 . The diverse physiological responses
of ANP are manifested by binding to its specific
cell-surface receptors. Membrane-bound form of
 .guanylyl cyclase-A GC-A also designated as Npra,
represents biologically active ANP receptor which
w xhas been cloned and sequenced 5,6 . The general
topological structure of Npra is consistent with at
least four distinct domains; ligand binding, trans-
membrane, protein kinase-like and guanylyl cyclase
catalytic regions. The production of second messen-
ger cGMP in response to ANP results from its bind-
ing to the extracellular domain of Npra which regu-
w xlates guanylyl cyclase catalytic domain 7 . ANP also
binds with high affinity to ANP-clearance receptor,
designated as Nprc which has been suggested to clear
w xANP from the circulation 8 and to play a mediatory
role in the ANP-dependent inhibitory action on
w xadenylyl cyclase 9,10 .
The mechanisms by which ANP exerts its effect
on various cellular and physiological responses have
not been clearly elucidated. In the present study, we
have examined the molecular mechanisms of ANP
 .action on protein kinase C PKC activity in PKC-a
cDNA transfected MA-10 cell line which expresses
the Npra at high density and has been used as a
model system to investigate the receptor-mediated
w xcellular and biochemical responses of ANP 6,11 .
The present results provide direct evidence that ANP
antagonizes the activation of PKC-a , through its
specific receptor, Npra and the second messenger
cGMP.
2. Materials and methods
2.1. Materials
 .  .ANP rat-28 , angiotensin II ANG II and en-
 .dothelin-1 ET-I were purchased from Peninsula
 .Laboratories Belmont, CA . 12-O-tetrade-
 .canoylphorbol-13-acetate TPA , phosphatidylserine
 .PS , dibutyryl-cAMP and 8-bromo-cGMP were pur-
 .chased from Sigma Chemical Co. St. Louis, MO .
EGF-R peptide was obtained from LC Laboratory
 . w 32 xWoburn, MA and g- P ATP was from Amersham
 .Arlington Heights, IL . A71915 was obtained from
 .Abbott Laboratories Abbott Park, IL and KT 5823
 .was purchased from Calbiochem San Diego, CA .
Tissue culture supplies were obtained from Life
 .Technologies Grand Island, NY . PKC-a cDNA,
cloned from human acute T-cell leukemia, jurkat cell
 .line was obtained from ATCC Rockville, MD . Pro-
tein kinase G-1a antibody was a gift from Dr.
Thomas Lincoln, University of Alabama at Birming-
ham, AL. All other chemicals were of reagent grade.
2.2. Cell culture
The MA-10 cell line was cultured in modified
Waymouth MB752r1 medium supplemented with
w x15% horse serum as previously described 12 . Mon-
key COS-7 cells were grown in Dulbecco’s modified
 .Eagle’s medium DMEM containing 100 unitsrml
penicillin, 100 mgrml streptomycin and 10% fetal
calf serum.
2.3. Plasmid construction
A full length cDNA of PKC-a was excised from
Bluescript vector by digesting with restriction en-
zyme EcoRI and subcloned into previously EcoRI-
digested site of mammalian expression vector
 .pcDNA3 Invitrogen, San Diego, CA . The pcDNA3
expression vector is designed for the expression of
foreign gene under the control of a cytomegalovirus
 .CMV promoter.
2.4. Transfection and hormonal treatments
 7.Cells 1=10 were electroporated with 20mg of
plasmid DNA at 220 volts for COS-7 and 170 volts
for MA-10 cells with a capacitance setting of 960
 .mF, using a Gene Pulser Bio-Rad, Richmond, CA ,
according to the manufacturer’s protocols. Trans-
fected cells were seeded in culture plates and the
media were replaced after 24 h. After 48 h, cells were
washed with culture medium containing 0.1% BSA
and subjected to appropriate hormonal treatments.
Transfection efficiency and reproducibility were ex-
amined with b x-gal 5-bromo-4-chloro-3-indolyl-b-
.D-galactopyranoside method according to MacGre-
w x 2q 2qgor 13 . Cells were washed with Ca rMg free
 .PBS, and fixed in 1% vrv formamide in PBS for
30 min. After which cells were rinsed twice with PBS
and stained overnight at room temperature in a solu-
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tion containing 1=PBS, 4 mM ferrocyanide, 4 mM
ferricyanide, 2 mM MgCl and 500 mgrml x-gal.2
Transfection efficiency was quantitated with micro-
scopic inspection of stained cells.
2.5. Preparation of cell extracts
Treated and control cells were washed twice with
 .phosphate buffered saline PBS , pH 7.5 and 20 mM
Tris-HCl, pH 7.5. Cells were scraped in buffer A,
 .consisted of 20 mM Tris-HCl pH 7.5 , 5 mM EDTA,
10 mM EGTA, 15 mM b-mercaptoethanol, 0.5%
Triton X-100, 5 mgrml aprotinin and 0.2 mM
 .phenylmethylsulfonylfluoride PMSF . Cells were
homogenized with 50 strokes of dounce homogenizer
and incubated for 30 min on ice. Homogenates were
centrifuged at 12 000=g for 15 min and super-
natants were applied onto a 0.5 ml DEAE-Sephacel
column pre-equilibrated with buffer-A. The column
was washed with 10 volumes of buffer-A containing
30 mM NaCl and PKC was eluted with buffer-A
containing 200 mM NaCl.
2.6. Assay of PKC acti˝ity
PKC activity in the DEAE-Sephacel purified
preparations was determined by incubating 15–20 ml
of the eluates in a 75 ml reaction mixture containing
 .8 mol% PS, 2.5 mM dithiothreitol DTT , 1 mM
 .calcium acetate, 75 mM EGF-R peptide substrate ,
15 mM magnesium acetate, 50 mM ATP and 10
w 32 x w xmCirml g- P ATP, essentially as described 14 .
After a 15 min incubation at 258C, the reaction was
 .stopped by adding 100 ml of 30% vrv acetic acid.
 .An aliquot 125 ml was removed from the reaction
mixture and applied to P-81 phosphocellulose paper
discs. After two washes with 5% acetic acid, the
paper discs were air-dried and bound radioactivity
was determined by scintillation counting. The spe-
cific activity of PKC was expressed as pmol 32P
transferred mgy1 substrate protein miny1. Total pro-
tein was estimated by Bio-Rad Protein Reagent Kit
 .Richmond, CA .
2.7. Western blotting
 .Partially purified proteins 15 mg from transfected
MA-10 cells were separated on 7.5% sodium dodecyl
 .sulfate SDS polyacrylamide gel, according to
w xLaemmli 15 and transferred onto Immobilon P
 .membrane Millipore, Bradford, MA by the methods
w xof Towbin et al. 16 . Non-specific binding was
blocked by overnight incubation of membrane in 5%
nonfat dry milk in PBS, pH 7.5, containing 0.1%
tween-20. Membranes were incubated with specific
PKC-a antibody Life Technologies, Grand Island,
. NY for 2–3 h and then washed three times 10 min
.each wash with PBS containing Tween-20. The
binding of primary antibody was detected with a
horseradish peroxidase conjugated anti-rabbit sec-
ondary antibody and revealed with Amersham en-
 .hanced chemiluminescence ECL detection system.
For immunological detection of cGMP-dependent
protein kinase-1a , samples were prepared according
w xto Keilback et al. 17 . Confluent MA-10 cells were
washed twice with ice-cold PBS and scraped in 8.1
mM NaHPO4, 1.8 mM KH PO , pH 7.2, 137 mM2 4
NaCl and 2.7 mM KCl. Cell pellets were suspended
in 20 mM K HPO , pH 7.0, 2 mM EDTA and 2 mM2 4
benzamidine. The suspension was freez-thawed three
times, homogenized with Teflon-glass homogenizer
and centrifuged at 15 000=g for 30 min at 48C. The
supernatant was used for Western blot analysis using
 .polyclonal antibodies of PKG-1a 1:500 and de-
tected by ECL method as described above.
2.8. Assay of intracellular cGMP
MA-10 cells were treated wtih ANP at 378C for 10
min in the presence of 0.2 mM 3-isobutyl-1-methyl-
 .xanthine IBMX . Cells were washed three times
with PBS and scraped in 0.05 M HCl and placed in
boiling water bath for 3 min. After centrifugation at
15 000=g for 15 min at 48C, supernatant was col-
lected and lyophilized. Samples were reconstituted
with acetate buffer and recentrifuged. In the super-
natants, cGMP was determined by RIA kit Biomedi-
.cal Technologies according to manufacturer’s proto-
cols.
3. Results
We examined the effect of ANP on PKC enzy-
matic activity in untransfected and PKC-a trans-
fected MA-10 cells which overexpress endogenous
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Fig. 1. Effect of ANP on TPA stimulated PKC activity in MA-10
. cells: a confluent MA-10 cells were pretreated with ANP 1=
y7 .  y7 .10 M andror treated with TPA 1=10 M for 15 min at
.378C. b The plasmid containing PKC-a cDNA insert
 .  .pcDNA3rPKC-a and vector pcDNA3 without the insert were
transfected in MA-10 cells by electroporation using 20 mg
cDNA. After 48 hr of transfection, cells were pretreated with
 y7 .  .ANP 1=10 M andror treated with vehicle DMSO only or
TPA for 15 min at 378C. After the appropriate treatments, whole
cell extracts were prepared and PKC activity were determined as
described under Section 2. Bar represents the means"S.E. of
4–5 different determinations. NT represents non-transfected cells.
Npra and produce high levels of cGMP in response to
ANP. Confluent MA-10 cells were treated with TPA
 y7 .1=10 M for 15 min at 378C which showed
approximately 1.6-fold induction in PKC activity as
compared with controls. However, treatment of cells
 y7 .  y7with both ANP 1=10 M and TPA 1=10
.M showed an approximately 15% inhibition in
 .TPA-induced PKC activity Fig. 1a . If MA-10 cells
were transfected with PKC-a construct and then
 y7 .treated with TPA 1=10 M , showed more than
4-fold increase in PKC activity as compared to the
untransfected cells or transfected with vector alone
 .Fig. 1b . After TPA-treatment, PKC activity in-
creased in a time-dependent manner, reaching to a
maximum level in 15 min and then gradually de-
 .clined data not shown . A residual PKC enzymatic
activity sensitive to Ca2qrPS was also evident in the
untransfected or cells transfected with vector alone.
The pretreatment of PKC-a transfected MA-10 cells
 y7 .with ANP 1=10 M , resulted in an approxi-
mately 40% decrease in TPA-stimulated PKC activity
 .Fig. 1b . Overexpression of PKC-a isoform in trans-
fected MA-10 cells was examined by Western blot
analysis, using specific polyclonal antibodies against
 .PKC-a Fig. 2a . Densitometric scanning of the ex-
posed hyperfilm ECL showed that expression of
Fig. 2. Immunodetection of PKC-a in pcDNA3 and
pcDNA3rPKC-a transfected MA-10 cells: After 48 h of trans-
fection, the whole cell extracts were prepared and partially
purified on DEAE-Sephacel column. Partial purified proteins 15
.mg from pcDNA3 and pcDNA3rPKC-a transfected cells were
separated and detected by ECL as described in Section 2. Repre-
sentative results are shown in panel a, and the quantitative
analyses by densitometric scanning are presented in panel b. Bars
represent the mean"S.E. of 3 different transfection and scan of
the films.
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Fig. 3. Inhibitory effect of ANP on ANG II and ET-1 stimulated
PKC activity in MA-10 cells: Cells were transfected with PKC-a
 .  .pcDNA3rPKC-a or vector pcDNA3 alone without the insert.
 y7 .Transfected cells were pretreated with ANP 1=10 M and
 .  y7 .  .  y7 .treated with a ANG II 1=10 M and b ET-1 1=10 M .
All treatments were carried out for 15 min. Cell extracts were
prepared and PKC activity was assayed as described in Section 2.
Bars represent the mean"S.E. of 4 experiments. NT represents
non-transfected cells.
PKC-a was 2.5 to 3-fold higher in PKC-a cDNA
transfected cells as compared to the cells transfected
 .with vector alone Fig. 2b . The integrity of PKC-a
 .cDNA pcDNA3rPKC-a clone used in these stud-
ies was examined in COS-7 cells. PKC-a cDNA
transfected COS-7 cells were exposed with TPA 1=
y7 .10 M which showed more than 20-fold stimula-
 .tion of PKC activity data not shown .
The agonist-induced PKC activity was maximally
inhibited at 1=10y7 M concentration of ANP. Both
 y7 .  y7 .ANG II 1=10 M and ET-1 1=10 M also
exerted a stimulatory effect on the PKC activity by
Table 1
Effect of ANP and 8-bromo cGMP on TPA stimulated PKC
activity in PKC-a transfected MA-10 cells
32Treatment Spec. act. pmol Pr
.min per mg protein
Control 22 000"2000
TPA 51 200"15000
ANPqTPA 310000"8000
StaurosporineqTPA 315000"13000
A71915qANPqTPA 473000"27000
8-Bromo-cGMPqTPA 349000"15000
8-Bromo-cGMPqANPqTPA 325000"11000
8-Bromo-cGMPqA71915qTPA 338000"7000
Dibutyryl-cAMPqTPA 487000"7000
KT5823q ANPqTPA 478000"14000
KT5823q8-Bromo-cGMPqTPA 492000"9000
The PKC-a cDNA was transiently transfected by electroporation
into MA-10 cells. After 48 h of transfection, cells were exposed
 y7 .  y7 . with TPA 1=10 M , ANP 1=10 M , staurosporine 1=
y6 .  y5 . 10 M 8-bromo-cGMP 1=10 M , dibutyryl-cAMP 1=
y5 .  y6 .  y6 .10 M , A71915 1=10 M and KT 5823 1=10 M .
Each treatments was performed for 15 min. After which, cells
were harvested and PKC was partially purified on a DEAE-Sep-
hacel column. The enzymatic activity of PKC was assayed as
described in Section 2. Values are mean"S.E. of 4–6 separate
experiments.
3–4-fold, respectively in PKC-a transfected MA-10
cells as compared to the cells transfected with vector
alone. Pretreatment of PKC-a transfected cells with
 y7 .ANP 1=10 M , antagonized the stimulatory ef-
Fig. 4. Effects of Npra antagonist A71915 on the ANP-stimulated
intracelluar formation of cGMP in MA-10 cells: the confluent
 y5 .cells were pretreated with Npra inhibitor A71915 1=10 M
 y7 .and treated with ANP 1=10 M for 10 min at 378C in the
presence of 0.2 mM IBMX. Cell extracts were prepared and
cGMP was estimated by radioimmunoassay as described in Sec-
tion 2. Data represent the mean"S.E. of 4 experiments.
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Fig. 5. Immunodetection of cGMP-dependent protein kinase-1a
 .PKG-1a in MA-10 cells: Aliquots of the cell extracts contain-
ing 25 mg total protein were separated on a 7.5% SDS-polyacryl-
amide gel and transferred to a Immobilon P membrane. PKG was
 .detected by anti-PKG-1a antibody 1:500 dilution and ECL
system as described in Section 2. Blot is the representative of the
three different experiments.
fects of both ANG II and ET-1 on PKC activity by
 .approx. 35–40% Fig. 3a and b . However, the ANP
treatment of either untransfected MA-10 cells or
transfected with vector alone caused only 20–22%
inhibition in ANG II- or ET-1 stimulated PKC activ-
ity. To examine if the inhibitory effect of ANP on
PKC activity was transmitted through the second
messenger cGMP, the Npra antagonist A71915 was
utilized which impairs production of cGMP in re-
sponse to ANP. Data from these experiments showed
that A71915 blocked the functional guanylyl cyclase
catalytic activity of Npra, as a result, the ANP was
unable to inhibit the agonist-induced PKC activity
 .Table 1 . The A71915 blocked the ANP-dependent
cGMP production by approximately 70% in MA-10
 .cells Fig. 4 . Staurosporine, an inhibitor of calcium-
dependent PKC isoform also blocked the agonist-
stimulated PKC activity.
A significant inhibition in TPA-dependent PKC
activity was also observed in the presence of 8-
bromo-cGMP in MA-10 cells. The inhibitory effect
of 8-bromo cGMP was considered specific because
the similar concentrations of dibutyryl-cAMP did not
show any effect on TPA-stimulated PKC activity
 .Table 1 . To further examine if the inhibitory actions
of ANP and 8-bromo-cGMP on the agonist-stimu-
lated PKC activity are mediated by cGMP-dependent
 .protein kinase protein kinase G; PKG , the cells
were pretreated with ANP and the PKC activators in
the presence of KT 5823, a specific inhibitor of
protein kinase G. As shown in Table 1, in the pres-
ence of KT5823, the inhibitory effects of both ANP
and 8-bromo-cGMP on the agonist-stimulated PKC
activity were significantly attenuated. ANP exerted
an inhibitory effect through receptor Npra by forma-
tion of intracellular cGMP in MA-10 cells. We also
identified the endogenous protein kinase G-1a in
MA-10 cells using polyclonal antibodies directed
 .against this kinase Fig. 5 .
4. Discussion
Data presented herein provide direct evidence that
ANP antagonizes the PKC activity stimulated by
TPA, ANG II and ET-1 in PKC-a cDNA transfected
MA-10 cells. The results suggest that the inhibitory
effect of ANP on agonist-stimulated PKC activity is
mediated by guanylyl cyclase-A receptor, Npra and
its second messenger cGMP. To substantiate if ANP
antagonized the PKC activity by the involvement of
Npra, we utilized the Npra antagonist A71915 which
blocks the effect of Npra to synthesize the intra-
w xcellular cGMP after ANP binding 18,19 . Treatment
of cells with ANP in the presence of Npra antagonist
A71915, reversed the inhibitory effect of ANP on
agonist-stimulated PKC activity, indicating direct role
of Npra in this process. To further understand the
mechanisms that cGMP inhibited the PKC activity,
we used A71915 which blocked the ANP dependent
cGMP production by approximately 70% in MA-10
cells. Previously we and others have suggested that
ANP inhibits the enzymatic activity and autophos-
phorylation of PKC in plasma membrane prepara-
w xtions of MA-10 and other cell systems 20–23 .
However, those previous studies on the inhibitory
effects of ANP, either on the autophosphorylation or
.the enzymatic activity of PKC did not provide the
specificity of PKC isoenzymes or the involvement of
a specific ANP receptor. The present results now
directly demonstrate that ANP inhibits the enzymatic
activity of PKC-a by involving the specific receptor,
Npra in intact cells.
PKC is a multifunctional serinerthreonine kinase
that is activated by Ca2qrphospholipids and phorbol
w xester 24,25 . On the basis of molecular cloning, PKC
( )R. Kumar et al.rBiochimica et Biophysica Acta 1356 1997 221–228 227
is composed of a family of 12 different isoenzymes
w x26,27 . These isoforms can be divided into three
subgroups: The classical PKCs or Ca2q-dependent
 . 2qa , b I, b II and g , novels PKCs or Ca -indepen-
  . . dent d , e , h L , B and m and atypical PKCs j , i
.and l not activated by phorbol esterrdiacylglycerol.
These isoforms show differential expression, cellular
distribution, and substrate specificity and have been
suggested to play varying roles in response to exter-
nal stimuli. By overexpressing PKC-a cDNA in MA-
10 cells, we have increased the agonist-stimulated
basal levels of PKC activity in these cells in response
to TPA, ANG II and ET-1. The effect of ANG II,
ET-1 and TPA on other cellular responses in MA-10
w xcells have also been reported 28–30 . MA-10 cells
predominantly contain high density of endogenous
Npra and ANP stimulates the production of intra-
w xcellular cGMP in a receptor-mediated manner 6 . We
also studied the effect of 8-bromo-cGMP on the
agonist-stimulated PKC activity in transfected and
control cells and the results showed that 8-bromo-
 .cGMP antagonized the PKC activity Table 1 . Since,
cGMP is considered a second messenger of ANP and
is produced by hormone-dependent activation of Npra,
it is implicated that intracellular cGMP activates pro-
 .tein kinase G cGMP-dependent protein kinase ,
which in turn, phosphorylates the target proteins dur-
ing the biological action of ANP. The KT 5823, a
specific inhibitor of cGMP-dependent protein kinase,
reversed the inhibitory effect of ANP on the agonist-
stimulated PKC activity, supporting the involvement
of cGMP-dependent protein kinase in this process.
Previous studies have shown that ANP also inhib-
ited the TPA- and ET-1-induced activation of mito-
 .gen-activated protein MAP kinases in a cGMP-de-
w xpendent manner 31 . Similarly, cGMP has also been
shown to antagonize the ANG II-mediated phos-
phdtidylcholine hydrolysis, C-kinase activation and
TPA-stimulated responses in other cell systems
w x32,33 . By contrast, studies have also shown that
TPA attenuates the ANP-dependent cGMP produc-
w xtion in vascular smooth muscle cells 34 and adreno-
w xcortical carcinoma cells 35 . The TPA-dependent
inhibitory effects on cGMP production have been
postulated to involve several mechanisms such as
w xactivation of phosphodiesterase 36 or desensitiza-
w xtion of Npra 37,38 . Earlier studies postulated that
the inhibition of guanylyl cyclase activity of Npra is
probably mediated by PKC-dependent phosphoryla-
w xtion 37,39 . However, more recently it has been
suggested that phorbol ester desensitizes the Npra,
possibly by dephosphorylation at specific residues
w xthrough PKC-dependent pathways 38 . If PKC in-
hibits a protein kinase which phosphorylates Npra or
activates a protein phosphatase that dephosphorylates
this receptor protein, remains to be investigated. Re-
gardless of the varying nature of these previous find-
ings, it seems to be certain that both Npra and PKC
interact negatively during biological action of ANP.
We have recently reported that ANP inhibits the
formation of IP in MA-10 cells in a cGMP-depen-3
w xdent manner 40 . Therefore it is possible that the
inhibitory effect of ANP on PKC activity might also
be linked with its inhibitory effect on IP formation.3
However, further studies are needed to strongly sup-
port these postulates in MA-10 and other cell sys-
tems.
In conclusion, the pretreatment with ANP and
8-bromo-cGMP antagonized the TPA, ANG II-
andror ET-1-stimulated PKC activity in PKC-a
cDNA transfected cells. The inhibitory effects of
ANP andror 8-bromo cGMP were reversed by
A71915, an antagonist of Npra and KT 5823, a
specific inhibitor of cGMP-dependent protein kinase,
respectively. Our results suggest that ANP acts as a
negative mediator of cross-talk between PKC-a and
Npra in a cGMP-dependent manner, probably involv-
ing the cGMP-dependent protein kinase.
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